ADC Therapeutics

1. ZYNLONTA + glofitamab topline4Q 2026ZYNLONTA + glofitamab topline, 4Q 2026, thesis-defining
2. ZYNLONTA + rituximab sBLA filing4Q 2026ZYNLONTA + rituximab sBLA filing, 4Q 2026, material
3. ZYNLONTA monotherapy MZL readout4Q 2026ZYNLONTA monotherapy MZL readout, 4Q 2026, material
4. ZYNLONTA corporate update1H 2027ZYNLONTA corporate update, 1H 2027, notable
5. ZYNLONTA + rituximab FL readout2Q 2027ZYNLONTA + rituximab FL readout, 2Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.